Recently a pan-GLUT inhibitor named glutor has been demonstrated to exhibit a potent antineoplastic action in the nanomolar concentration range against cancer cells of diverse origins (Reckzeh and Waldmann, 2020a; Reckzeh and Waldmann, 2020b; Temre et al., 2022). Here, SLC2A1 is linked to cancer.